Hemostemix Inc. (CVE:HEM – Get Free Report) rose 25% on Thursday . The stock traded as high as C$0.36 and last traded at C$0.35. Approximately 1,444,856 shares changed hands during trading, an increase of 111% from the average daily volume of 684,559 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 7.1 %
The company has a market cap of C$32.67 million, a price-to-earnings ratio of -18.75 and a beta of 0.20. The business has a 50-day simple moving average of C$0.13 and a two-hundred day simple moving average of C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- What Investors Need to Know to Beat the Market
- Bloom Energy: Powering the Future With Decentralized Energy
- Overbought Stocks Explained: Should You Trade Them?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
